Division of Surgical Research/Department of Surgery, Lifespan-Rhode Island Hospital and Brown University , Providence, Rhode Island.
Department Pathology and Laboratory Medicine, Lifespan-Rhode Island Hospital and Brown University , Providence, Rhode Island.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G106-G114. doi: 10.1152/ajpgi.00204.2018. Epub 2018 Nov 15.
The liver is an organ that, when dysfunctional in a septic patient, is strongly associated with morbidity and mortality. Understanding the pathophysiology of liver failure during sepsis may lead to improved diagnostics and potential therapeutic targets. Historically, programmed cell death receptor (PD) ligand 1 (PD-L1) has been considered the primary ligand for its checkpoint molecule counterpart, PD-1, with PD-L2 rarely in the immunopathological spotlight. PD-1 and PD-L1 contribute to liver dysfunction in a murine cecal ligation and puncture (CLP) model of sepsis, but virtually nothing is known about PD-L2's role in sepsis. Therefore, our central hypothesis was that sepsis-induced changes in hepatic PD-L2 expression contributed to worsened liver function and, subsequently, more pronounced morbidity and mortality. We found that although PD-L1 gene deficiency attenuated the hepatic dysfunction seen in wild-type mice after CLP, the loss of PD-L2 appeared to actually worsen indices of liver function along with a trend toward higher liver tissue vascular permeability. Conversely, some protective effects of PD-L2 gene deletion were noted, such as reduced liver/peritoneal bacterial load and reduced IL-6, IL-10, and macrophage inflammatory protein 2 levels following CLP. These diverse actions, as well as the unique expression pattern of PD-L2, may explain why no overt survival advantage could be witnessed in the septic PD-L2 mice. Taken together, these data suggest that although PD-L2 has some selective effects on the hepatic response seen in the septic mouse, these factors are not sufficient to alter septic mortality in this adult murine model. NEW & NOTEWORTHY Our study shows not only that ligands of the checkpoint protein PD-1 respond inversely to a stressor such as septic challenge (PD-L2 declines, whereas PD-L1 rises) but also that aspects of liver dysfunction increase in septic mice lacking the PD-L2 gene. Furthermore, these differences in PD-L2 gene-deficient animals culminated in the abrogation of the survival advantage seen in the septic PD-L1-knockout mice, suggesting that PD-L2 may have roles beyond a simple immune tolerogen.
肝脏是一种器官,如果在脓毒症患者中出现功能障碍,与发病率和死亡率密切相关。了解脓毒症期间肝衰竭的病理生理学可能会导致改进的诊断和潜在的治疗靶点。从历史上看,程序性细胞死亡受体 (PD) 配体 1 (PD-L1) 一直被认为是其检查点分子对应物 PD-1 的主要配体,而 PD-L2 很少成为免疫病理学的焦点。PD-1 和 PD-L1 在脓毒症的盲肠结扎和穿刺 (CLP) 小鼠模型中导致肝功能障碍,但实际上对 PD-L2 在脓毒症中的作用知之甚少。因此,我们的中心假设是,脓毒症诱导的肝 PD-L2 表达变化导致肝功能恶化,进而导致更明显的发病率和死亡率。我们发现,尽管 PD-L1 基因缺失减轻了 CLP 后野生型小鼠的肝功能障碍,但 PD-L2 的缺失似乎实际上使肝功能指标恶化,同时肝组织血管通透性呈上升趋势。相反,PD-L2 基因缺失也观察到一些保护作用,例如 CLP 后肝/腹膜细菌负荷降低和 IL-6、IL-10 和巨噬细胞炎症蛋白 2 水平降低。这些不同的作用以及 PD-L2 的独特表达模式可能解释了为什么在脓毒症 PD-L2 小鼠中没有明显的生存优势。总之,这些数据表明,尽管 PD-L2 对脓毒症小鼠中观察到的肝反应有一些选择性作用,但这些因素不足以改变该成年小鼠模型中的脓毒症死亡率。新的和值得注意的是我们的研究不仅表明 PD-1 的检查点蛋白配体对脓毒症等应激源的反应相反(PD-L2 下降,而 PD-L1 上升),而且在缺乏 PD-L2 基因的脓毒症小鼠中,肝功能障碍的某些方面增加。此外,PD-L2 基因缺失动物的这些差异最终导致了在脓毒症 PD-L1 敲除小鼠中观察到的生存优势的消除,这表明 PD-L2 可能具有超越简单免疫耐受原的作用。